Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

FDA grants orphan drug status to Almirall product for pemphigus vulgaris

Feb. 4, 2015

Cutanea Life Sciences initiates phase II trial of CLS-003 for cutaneous warts

Jan. 28, 2015

Aclaris Therapeutics reports data from phase IIb trial of A-101

Jan. 28, 2015

FDA approves Cosentyx for moderate to severe plaque psoriasis

Jan. 22, 2015

European Commission approves Novartis' Cosentyx in plaque psoriasis

Jan. 21, 2015

Otezla receives approval in the E.U. for the treatment of psoriasis and psoriatic arthritis

Jan. 19, 2015

Cimzia begins phase III program for psoriasis

Jan. 13, 2015

Sirnaomics files Chinese IND application for STP-705 for hypertrophic scars

Jan. 7, 2015

Helix BioMedix patents human C-X-C chemokine-derived peptides

Jan. 7, 2015

Preclinical investigation of a small-molecule JAK1/TYK2 inhibitor for psoriasis

Jan. 5, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 16, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...